Across GLP-1 withdrawal trials, about 60% of lost weight returned by 52 weeks, and a tirzepatide withdrawal trial also measured substantial regain
The results of ACHIEVE-3 highlight the potential advantages of Orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions thats a combination that could matter significantly to people managing their disease day in and day out, said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health
This interdependence is yet to be systematically investigated
A few words of caution if starting a GLP-1 agonist Titrate your dosage slowly and carefully
The exact number of draws depends on your dosing protocol and vial concentration
This gives your body more time to adjust to the treatment